Not Yet RecruitingPhase 3

Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department

226 participantsStarted 2026-05-01

Plain-language summary

Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia. Objectives: Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises. Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib. Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups. Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned. Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * An adult (\>18 years) sickle cell disease patient presents with moderate-severe vaso-occlusive crisis (VOC) to the ED. Exclusion Criteria: * Non-VOC Pain (e.g. Acute chest syndrome, sequestration, septic arthritis, Etc.) * Weight less than 50 KG * Recurrent visits \> one visit/ week * Opioids within 24hrs * NSAIDs within 24hrs * Contraindications to NSAIDs (e.g. allergy, Asthma, CKD, pregnancy, Etc.) * Lactating mothers * Visited another health institution within 24hrs

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Pain reduction at 60 mins.

Timeframe: 60 mintues

Trial details

NCT IDNCT06315920

SponsorOman Medical Speciality Board

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2028-05-01

Contact for this trial

USAMA ALKHALASI, MD

+96894094001 u.alkhalasi@gmail.com

View on ClinicalTrials.gov More Sickle-Cell Disease with Crisis trials